Description of Invention:
Monokine induced by IFN-gamma(Mig), which is structurally related to interferon-inducible protein 10 (IP-10), has been shown to exhibit antitumor activity. Mig is a member of the alpha chemokine family. Members of this chemokine family, PF4, PBP, CTAP-III, betaTG, NAP-2, IL-8, GROalpha, GRObeta, GROgamma, and IP-10, have been shown to act as an angiogenic or angiostatic factor. This invention relates to the use of Mig to promote the death of tumor tissue. It also relates to a method of inhibiting angiogenesis at a tumor site using Mig.
Potential Area of Application:
cancer therapeutic
inhibitor of angiogenesis
Inventors:
G Tosato (FDA) J Farber (NIAID) C Sgardari (FDA)
Patent Status:
DHHS Reference No. E-032-1997/0
Related Technologies: U.S. Patent Application No. 08/455,079 filed 31 May 1995 entitled "Interferon-Inducible 10 (IP-10) is a Potent Inhibitor of Angiogenesis"; inventors are G Tosato, AL Angiolillo, and C Sgardari.
Relevant Publication:
C Sgadari, JM Farber, AL Angiolillo, F Liao, J Teruya-Feldstein, PR Burd, L Yao, G Gupta, C Kanegane, G Tosato: Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 1997 Apr 15;89(8):2635-43.
JM Farber: Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997 Mar;61(3):246-57.
Licensing Status: This technology is no longer available for licensing.
Portfolios: Internal Medicine Cancer
Cancer -Therapeutics-Biological Response Modifiers Internal Medicine-Therapeutics-Other Cancer -Therapeutics Internal Medicine-Therapeutics
For Additional Information Please Contact: Mojdeh Bahar J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-2950
Email: baharm@mail.nih.gov
Fax: (301) 402-0220
